ANIP News and Press, ANI Pharmaceuticals Inc. From 12/21/23

2023-12-21 15:26:31 ET Summary Today, we look at generic drug concern Amphastar Pharmaceuticals, Inc., whose stock has more than doubled over the past year. The company also made a major acquisition this spring, but insider selling did pick up in November. What's ahead for Amp...

BAUDETTE, Minn., Nov. 22, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President & CEO, will participate at the Piper Sandler 35th Annual Healthcare Conference in New York City as follows: To schedule a 1x1 mee...

2023-11-21 16:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-08 11:59:03 ET ANI Pharmaceuticals, Inc. (ANIP) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Judy DiClemente - Insight Communications IR Nikhil Lalwani - President and CEO Stephen Carey - CFO Conference Call Part...

2023-11-08 06:51:52 ET More on ANI Pharmaceuticals 3 Catalysts Could Drive ANI Pharmaceuticals' PPS Growth Through November 2023 ANI Pharma: Slow And Steady Revenue Generator ANI Pharmaceuticals Q3 2023 Earnings Preview ANI Pharma wins FDA nod for generic Est...

Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3% ; net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45 -- -- R...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

ANI Pharmaceuticals Inc. (ANIP) is expected to report $0.56 for Q3 2023

2023-11-07 12:38:56 ET More on ANI Pharmaceuticals 3 Catalysts Could Drive ANI Pharmaceuticals' PPS Growth Through November 2023 ANI Pharma: Slow And Steady Revenue Generator ANI Pharmaceuticals, Inc. (ANIP) Q2 2023 Earnings Call Transcript ANI Pharma wins FD...

2023-11-06 10:28:09 ET Summary ANIP's PPS has gained 63.41% YTD and is expected to continue growing. ANIP should record its fifth consecutive quarter beating earnings and revenue consensus. ANIP's Sovuna, a unique version of Hydroxychloroquine sulfate, and a new 1-ml vial vers...